BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20536395)

  • 1. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.
    Hook V; Hook G; Kindy M
    Biol Chem; 2010 Aug; 391(8):861-72. PubMed ID: 20536395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein.
    Hook VY; Kindy M; Hook G
    J Biol Chem; 2008 Mar; 283(12):7745-53. PubMed ID: 18184658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid-β in hAβPP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition.
    Hook G; Kindy M; Hook V
    J Alzheimers Dis; 2023; 93(1):33-46. PubMed ID: 36970896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence.
    Kindy MS; Yu J; Zhu H; El-Amouri SS; Hook V; Hook GR
    J Alzheimers Dis; 2012; 29(4):827-40. PubMed ID: 22337825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
    Kimura A; Hata S; Suzuki T
    J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
    Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
    Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases.
    Cai Z; Wang C; He W; Chen Y
    Curr Alzheimer Res; 2018; 15(11):1045-1052. PubMed ID: 29962345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
    Devi L; Ohno M
    Eur J Neurosci; 2010 Jan; 31(1):110-8. PubMed ID: 20092558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
    Johnson ECB; Ho K; Yu GQ; Das M; Sanchez PE; Djukic B; Lopez I; Yu X; Gill M; Zhang W; Paz JT; Palop JJ; Mucke L
    Mol Neurodegener; 2020 Sep; 15(1):53. PubMed ID: 32921309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein.
    Hook VY; Kindy M; Reinheckel T; Peters C; Hook G
    Biochem Biophys Res Commun; 2009 Aug; 386(2):284-8. PubMed ID: 19501042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
    Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
    J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Swedish dilemma - the almost exclusive use of APPswe-based mouse models impedes adequate evaluation of alternative β-secretases.
    Armbrust F; Bickenbach K; Marengo L; Pietrzik C; Becker-Pauly C
    Biochim Biophys Acta Mol Cell Res; 2022 Mar; 1869(3):119164. PubMed ID: 34699873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.
    Buggia-Prevot V; Sevalle J; Rossner S; Checler F
    J Biol Chem; 2008 Apr; 283(15):10037-47. PubMed ID: 18263584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
    Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
    J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.